TC BioPharm Announces Pricing of $3.5 Million Public Offering
- None.
- None.
The announcement of TC BioPharm's public offering is a strategic financial move that warrants attention from investors and industry analysts alike. The decision to price American Depositary Shares (ADSs) and accompanying Series E Warrants at $2.00 per unit signals a potential for capital influx, which could be pivotal in advancing the company's clinical stage gamma-delta T cell therapies. This pricing strategy may reflect the company's confidence in its technology and the anticipated demand from investors.
From a biotechnology perspective, the development of allogeneic gamma-delta T cell therapies represents a cutting-edge approach in oncology. The funds raised through this offering could accelerate clinical trials, potentially leading to breakthroughs in cancer treatment. However, it's crucial to monitor the burn rate and the progress of clinical outcomes to assess the long-term viability of the investment.
Investors should consider the inherent risks associated with biotech firms at this stage, including clinical trial failures, regulatory hurdles and the competitive landscape. The exercise price of the Series E Warrants (£1.5814 per ADS) is another factor to analyze, as it may offer insights into the company's future pricing expectations and market valuation.
TC BioPharm's public offering is a noteworthy event for market participants, as it directly affects the company's capital structure and shareholder value. The offering's success will largely depend on investor perception of the company's growth prospects and the attractiveness of the $2.00 pricing point. A successful capital raise could improve the company's financial position, allowing it to invest more aggressively in research and development.
However, it is essential to evaluate the dilutive impact of the offering on existing shareholders. The issuance of additional ADSs increases the number of outstanding shares, which could lead to earnings dilution if not offset by proportional revenue growth from the company's cancer therapies. The long-term implications for the stock's performance hinge on the balance between capital infusion and dilution effects.
Moreover, the associated Series E Warrants provide leverage potential for investors but introduce additional layers of complexity. The warrants' terms, including the exercise price and five-year expiration, should be analyzed in the context of the company's projected growth trajectory and industry benchmarks.
In the context of investment strategy, TC BioPharm's public offering represents an opportunity for investors to engage with a company at the forefront of cancer treatment innovation. The offering's structure, with both ADSs and Series E Warrants, provides a two-tier investment approach. Investors can gain immediate equity through ADSs and a longer-term option through the warrants.
The exercise price set for the Series E Warrants is a critical detail. It suggests a level of future value that the company expects to achieve, which can be a signal for investors to assess the growth potential and risk profile of the investment. The five-year lifespan of the warrants offers a long-term horizon, aligning with the extended timelines typically associated with biotech product development and commercialization.
It is essential for investors to conduct due diligence on TC BioPharm's pipeline, regulatory interactions and market dynamics for gamma-delta T cell therapies. The biotech sector's volatility and the high stakes of clinical trial results necessitate a comprehensive risk assessment before participating in such an offering.
H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.
The gross proceeds to the Company from the offering are expected to be
A registration statement on Form F-1 (File No. 333-274244) relating to the securities described above has been filed with the Securities and Exchange Commission, or the SEC, and was declared effective by the SEC on December 18, 2023. The offering will be made only by means of a prospectus, which is part of the effective registration statement. A preliminary prospectus relating to the offering has been filed with the SEC. When available, electronic copies of the final prospectus may be obtained for free on the SEC's website located at http://www.sec.gov and may also be obtained by contacting H.C. Wainwright & Co., LLC at 430 Park Avenue, 3rd Floor,
The Company also has agreed that a certain existing warrant to purchase up to an aggregate of 623,750 ADSs of the Company that was previously issued on September 5, 2023, at an exercise price of
This press release does not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.
About TC BioPharm (Holdings) PLC
TC BioPharm is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cell therapies for the treatment of cancer with human efficacy data in acute myeloid leukemia. Gamma-delta T cells are naturally occurring immune cells that embody properties of both the innate and adaptive immune systems and can intrinsically differentiate between healthy and diseased tissue. TC BioPharm uses an allogeneic approach in both unmodified and CAR modified gamma-delta T cells to effectively identify, target and eradicate both liquid and solid tumors in cancer. TC BioPharm is the leader in developing gamma-delta T cell therapies, and the first company to conduct phase II/pivotal clinical studies in oncology. The Company is conducting two investigator-initiated clinical trials for its unmodified gamma-delta T cell product line - Phase 2b/3 pivotal trial for OmnImmune® in treatment of acute myeloid leukemia using the Company's proprietary allogeneic CryoTC technology to provide frozen product to clinics worldwide. TC BioPharm also maintains a robust pipeline for future indications in solid tumors as well as a significant IP/patent portfolio in the use of CARs with gamma-delta T cells and owns our manufacturing facility to maintain cost and product quality controls.
Forward Looking Statements
This press release may contain statements of a forward-looking nature relating to future events, including, but not limited to, statements relating to closing of the offering and satisfaction of closing conditions of the offering, the expected gross proceeds from the offering and statements regarding the anticipated use of proceeds from the offering. These forward-looking statements are subject to the inherent uncertainties in predicting future results and conditions. These statements reflect our current beliefs, and a number of important factors could cause actual results to differ materially from those expressed in this press release. We undertake no obligation to revise or update any forward-looking statements, whether as a result of new information, future events or otherwise. The reference to the website of TC BioPharm has been provided as a convenience, and the information contained on such website is not incorporated by reference into this press release.
View original content:https://www.prnewswire.com/news-releases/tc-biopharm-announces-pricing-of-3-5-million-public-offering-302019005.html
SOURCE TC BioPharm
